Compounds Discovered In Asia Expected To Enter Clinic In Three Years, Pfizer Says
This article was originally published in PharmAsia News
Executive SummarySINGAPORE - Pfizer expects to see drugs discovered and developed in Asia brought into the clinic in about three years, Pfizer's Pharma Therapeutics R&D Head Martin Mackay told local reporters April 7 during a press conference at the company's Clinical Research Unit at Raffles Hospital in Singapore
You may also be interested in...
The JV with Shanghai Zhangjiang Biomedical Industry Venture Capital will fund the development and commercialization of MicuRx’s novel antibiotic MRX-I for the Chinese market.
The launch of a clinical trials registry in Singapore is another step in the wealthy city-state’s efforts to serve as a treatment hub in Asia for cutting-edge therapies.
South Korean Plan To Shorten IND Approvals Raises Competition With Singapore For Clinical Trials Hub
Patient differences will come into sharper relief in attracting Phase I clinical trials if, as expected, South Korea cuts its IND approval timeline near par with Singapore.